CYTK Dec 2024 33.000 call
| Previous close | 24.30 |
| Open | 24.30 |
| Bid | 24.90 |
| Ask | 28.40 |
| Strike | 33.00 |
| Expiry date | 2024-12-20 |
| Day's range | 24.30 - 24.30 |
| Contract range | N/A |
| Volume | |
| Open interest | 13 |
GlobeNewswireCytokinetics Presents Additional Data from SEQUOIA-HCM at the HCMS Scientific Sessions
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data from SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), were presented at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions by Anjali T. Owens, M.D., Med
- GlobeNewswire
Cytokinetics Announces Call for Proposals for Its Seventh Annual Communications Grant Program
Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular Diseases Deadline for Applications is November 4th, 2024 SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for the seventh annual Cytokinetics Communications Grant Program. The program will award five grants in the amount of $20,000 each to patient advocacy organizations serv
Investor's Business DailyHow Edgewise, Up 55%, Is Hoping To Edge Out Bristol, Cytokinetics In Heart Disease
Edgewise Therapeutics stock skyrocketed on Thursday after a single dose of its drug improved heart function in cardiomyopathy patients.
